Stocks and Finance

Sangamo BioSciences

Sangamo BioSciences 10/3/2011

07:09 : Sangamo BioSciences (SGMO) drops 36.8% premarket after announcing it didn' - Sangamo BioSciences (SGMO) drops 36.8% premarket after announcing it didn't meet the clinical endpoints it hoped to achieve in a Phase 2b trial of its SB-509 drug for treating diabetic neuropathy. As a result, Sangamo plans ...
Source : seekingalpha-com
actualidad Sangamo BioSciences -


Biotechnology

Pharmaceuticals

Medical Supplies

Medical Equipment

Health Care Providers

Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts